Antibody Information

General Information of This Antibody
Antibody ID
ANI0WTWYF
Antibody Name
Anti-MSLN antibody Fab fragment
Antibody Type
Monoclonal antibody (mAb)
Antibody Subtype
Humanized IgG1 Fab
Antigen Name
Mesothelin (MSLN)
  Antigen Info 
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
RG7787 [Investigative]
 ADC Info 
Revealed Based on the Cell Line Data
Click To Hide/Show 24 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.10 ng/mL
Positive MSLN expression (MSLN+++/++)
Method Description
RG7787 activity by combination with DDR1 inhibitor 7rh in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model Skin squamous cell carcinoma A-431 cells CVCL_0037
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.40 ng/mL
Positive MSLN expression (MSLN+++/++)
Method Description
RG7787 activity by combination with DDR1 inhibitor 7rh in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model Breast ductal carcinoma HCC70 cells CVCL_1270
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.70 ng/mL
Positive MSLN expression (MSLN+++/++)
Method Description
RG7787 activity by combination with DDR1 siRNA in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model Pancreatic ductal adenocarcinoma AsPC-1 cells CVCL_0152
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
1.00 ng/mL
Positive MSLN expression (MSLN+++/++)
Method Description
RG7787 activity by combination with DDR1 inhibitor 7rh in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model Breast carcinoma SUM149PT cells CVCL_3422
Experiment 5 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
1.50 ng/mL
Positive MSLN expression (MSLN+++/++)
Method Description
RG7787 activity by combination with DDR1 siRNA in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model Skin squamous cell carcinoma A-431 cells CVCL_0037
Experiment 6 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
1.50 ng/mL
Positive MSLN expression (MSLN+++/++)
Method Description
RG7787 activity by combination with DDR1 siRNA in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model Peritoneal malignant mesothelioma HAY cells CVCL_N813
Experiment 7 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
2.00 ng/mL
Positive MSLN expression (MSLN+++/++)
Method Description
RG7787 activity by combination with DDR1 inhibitor 7rh in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model Pancreatic ductal adenocarcinoma KLM-1 cells CVCL_5146
Experiment 8 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
2.00 ng/mL
Positive MSLN expression (MSLN+++/++)
Method Description
RG7787 activity by combination with DDR1 siRNA in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model Human papillomavirus-related endocervical adenocarcinoma KB cells CVCL_0372
Experiment 9 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
2.00 ng/mL
Positive MSLN expression (MSLN+++/++)
Method Description
RG7787 activity in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model Skin squamous cell carcinoma A-431 cells CVCL_0037
Experiment 10 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
3.00 ng/mL
Positive MSLN expression (MSLN+++/++)
Method Description
RG7787 activity by combination with DDR1 inhibitor 7rh in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model . L55S cells Homo sapiens
Experiment 11 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
3.70 ng/mL
Positive MSLN expression (MSLN+++/++)
Method Description
RG7787 activity by combination with DDR1 siRNA in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model Pancreatic ductal adenocarcinoma KLM-1 cells CVCL_5146
Experiment 12 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
4.00 ng/mL
Positive MSLN expression (MSLN+++/++)
Method Description
RG7787 activity in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model Breast ductal carcinoma HCC70 cells CVCL_1270
Experiment 13 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
5.00 ng/mL
Positive MSLN expression (MSLN+++/++)
Method Description
RG7787 activity by combination with DDR1 inhibitor 7rh in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model Peritoneal malignant mesothelioma HAY cells CVCL_N813
Experiment 14 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
6.00 ng/mL
Positive MSLN expression (MSLN+++/++)
Method Description
RG7787 activity by combination with DDR1 inhibitor 7rh in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model Human papillomavirus-related endocervical adenocarcinoma KB cells CVCL_0372
Experiment 15 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
8.00 ng/mL
Positive MSLN expression (MSLN+++/++)
Method Description
RG7787 activity by combination with control si in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model Pancreatic ductal adenocarcinoma KLM-1 cells CVCL_5146
Experiment 16 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
10.00 ng/mL
Positive MSLN expression (MSLN+++/++)
Method Description
RG7787 activity in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model . L55S cells Homo sapiens
Experiment 17 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
11.00 ng/mL
Positive MSLN expression (MSLN+++/++)
Method Description
RG7787 activity by combination with control si in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model Skin squamous cell carcinoma A-431 cells CVCL_0037
Experiment 18 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
11.00 ng/mL
Positive MSLN expression (MSLN+++/++)
Method Description
RG7787 activity by combination with control si in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model Peritoneal malignant mesothelioma HAY cells CVCL_N813
Experiment 19 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
11.00 ng/mL
Positive MSLN expression (MSLN+++/++)
Method Description
RG7787 activity in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model Pancreatic ductal adenocarcinoma KLM-1 cells CVCL_5146
Experiment 20 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
11.00 ng/mL
Positive MSLN expression (MSLN+++/++)
Method Description
RG7787 activity in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model Breast carcinoma SUM149PT cells CVCL_3422
Experiment 21 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
35.00 ng/mL
Positive MSLN expression (MSLN+++/++)
Method Description
RG7787 activity in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model Peritoneal malignant mesothelioma HAY cells CVCL_N813
Experiment 22 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
40.00 ng/mL
Positive MSLN expression (MSLN+++/++)
Method Description
RG7787 activity by combination with control si in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model Human papillomavirus-related endocervical adenocarcinoma KB cells CVCL_0372
Experiment 23 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
40.00 ng/mL
Positive MSLN expression (MSLN+++/++)
Method Description
RG7787 activity by combination with control si in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model Pancreatic ductal adenocarcinoma AsPC-1 cells CVCL_0152
Experiment 24 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) > 100 ng/mL Positive MSLN expression (MSLN+++/++)
Method Description
RG7787 activity in MSLN-expressing cell lines. Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted antibodies (0-167 nM in starvation medium) for 1 h.
In Vitro Model Human papillomavirus-related endocervical adenocarcinoma KB cells CVCL_0372
References
Ref 1 Anticancer Effects of Mesothelin-Targeted Immunotoxin Therapy Are Regulated by Tyrosine Kinase DDR1. Cancer Res. 2016 Mar 15;76(6):1560-8. doi: 10.1158/0008-5472.CAN-15-2401. Epub 2015 Dec 30.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.